<DOC>
	<DOCNO>NCT00401739</DOCNO>
	<brief_summary>Acute myeloid leukemia ( AML ) heterogeneous group diseases characterize uncontrolled proliferation myeloid line white blood cell impaired production normal blood cell . If untreated , patient die infection bleed usually matter week . CSL360 neutralise monoclonal antibody believe target cell think drive AML effectively kill standard treatment . The aim study determine biologically active dose CSL360 generate understand rational schedule administration future study .</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetics CSL360 Treatment Acute Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Clinical diagnosis acute myeloid leukemia Recent bone marrow biopsy Prior treatment medically unfit standard therapy Peripheral blood blast count &gt; 30 x 109/L , rapidly progressive AML Previous solid organ transplant Active GvHD immunosuppression Concurrent treatment anticancer therapy Active infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>